Abstract
In “Test” region 75% of women (aged 24-64) are screened regularly, meaning every 3 years. A cost-effectiveness analysis shows that, considering regional tariffs, the multiple cohort (12-year-old + 25-year-old women) vaccination strategy with a 50% coverage, even if the coverage is much lower than 90%, could prevent 8 cases of cervicocarcinoma and 4 related deaths more than the vaccination of only 12-year-old girls, and thus proves to be cost-effective (8,721 €/QALY).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Farmeconomia. Health economics and therapeutic pathways
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
